Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials

---

Ruperto N., Brunner H. I. , Quartier P., Constantin T., Wulffraat N. M. , Horneff G., ...More

ANNALS OF THE RHEUMATIC DISEASES, vol.77, no.12, pp.1710-1719, 2018 (Journal Indexed in SCI)

• Publication Type: Article / Article
• Volume: 77 Issue: 12
• Publication Date: 2018
• Doi Number: 10.1136/annrheumdis-2018-213150
• Journal Name: ANNALS OF THE RHEUMATIC DISEASES
• Journal Indexes: Science Citation Index Expanded, Scopus
• Page Numbers: pp.1710-1719

Abstract

Objectives To evaluate the long-term efficacy and safety of canakinumab in patients with active systemic juvenile idiopathic arthritis (JIA).